Novartis Exjade Trial Failed To Show Non-Inferiority To Desferal, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Subset analysis conducted by Novartis may show Exjade benefit in certain patients at higher doses, according to FDA background documents for the Sept. 29 Blood Products Advisory Committee meeting.You may also be interested in...
Novartis' Exjade Recommended For Approval Under Broader Indication
FDA's Blood Products Advisory Committee agreed that data for the oral chelating agent from primarily thalassemia patients may be extrapolated to transfusional hemosiderosis.
Novartis' Exjade Recommended For Approval Under Broader Indication
FDA's Blood Products Advisory Committee agreed that data for the oral chelating agent from primarily thalassemia patients may be extrapolated to transfusional hemosiderosis.
Novartis' Exjade Goes To Blood Products Committee Sept. 29
Advisory committee likely to discuss iron chelator’s failure to show non-inferiority to existing treatment in 1,000-patient clinical program.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: